ITCI News and Press, Intra-Cellular Therapies Inc. From 05/22/24

2024-05-22 01:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-07 13:47:10 ET Intra-Cellular Therapies, Inc. (ITCI) Q1 2024 Earnings Conference Call May 07, 2024, 8:30 AM ET Company Participants Juan Sanchez - Vice President of Corporate Communications and Investor Relations Sharon Mates - Founder, Chairman and Chief Exe...

2024-05-07 07:33:12 ET More on Intra-Cellular Therapies Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data Intra-Cellular Therapies Is On Fire Intra-Cel...

CAPLYTA Q1 2024 net product sales were $144.8 million , compared to $94.7 million for the same period in 2023 , representing a 53% increase CAPLYTA’s strong prescription uptake continues: Q1 2024 CAPLYTA total prescripti...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-05-06 10:37:40 ET More on Intra-Cellular Therapies Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data Intra-Cellular Therapies Is On Fire Read th...

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast...

2024-04-30 04:38:06 ET Summary The share price reaction of Intra-Cellular Therapies was not as strong as expected after the positive phase 3 results of Caplyta in major depressive disorder. Positive MDD results represent another de-risking event for the drug and should open up ano...

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that...

2024-04-18 02:47:32 ET More on Intra-Cellular Therapies Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies gains on meeting main goal in trial for its depression treatment I...